Please provide your email address to receive an email when new articles are posted on . The standardized overall prevalence rate of lichen planus was 0.15%. Among those treated with systemic ...
Panelists discuss how the pooled 3-year data for delandistrogene moxeparvovec show sustained motor function stabilization and less deterioration compared with natural history, providing confidence in ...
Panelists discuss how data from MDA 2025 demonstrate that delandistrogene moxeparvovec (gene therapy for DMD) shows statistically significant improvements in motor function outcomes including North ...
Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart and elebsiran, a combination therapy developed for chronic Hepatitis B in ...
The last time I wrote an article on Alector, Inc. (ALEC), I analyzed its enormous potential in using its TREM2 receptor drug AL002 being studied in the phase 2 INVOKE-2 trial, which was targeting ...
Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression ...
A probabilistic data linkage between Iowa Cancer Registry (ICR) and an Iowa oncology clinic through CancerLinQ data was conducted for cases diagnosed between 2009 and 2018. Demographic, cancer, and ...
HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively As previously ...
Shocking CDC statistics show the number of US children that received mental health treatment in 2021
Dismal numbers released Tuesday by the CDC’s National Center for Health Statistics indicate 15 percent of America's children aged five to 17 recently received treatmentt for mental health conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback